儿科设备创新:对食品和药物管理局随时间的授权进行分析
Jonathan Dubin1,2, Krish Sardesai1, Caleb Grote1,3
1University of Missouri-Kansas City, Kansas City, Missouri.
概括
儿童整形器械创新显著落后于成人器械,很少有专门为儿童设计的新型植入物. 这种缺乏创新需要重新定位成人植入物,突出了儿科护理的关键未满足需求.
科学领域:
- 整形外科手术 整形外科手术
- 生物医学工程 生物医学工程
- 监管科学 监管科学
背景情况:
- 对于儿科患者而言,存在有限的新型骨科设备.
- 成人植入物经常被重新用于儿科使用,造成风险.
- 儿科设备的创新并没有跟上成人设备的发展步伐.
研究的目的:
- 量化和描述随时间推移的儿科整形器械创新.
- 评估FDA授权的设备中儿科专用创新的程度.
- 分析公司规模对儿科设备开发的影响.
主要方法:
- 分析了美国食品和药物管理局 (FDA) 授权的骨科设备.
- 通过人道主义设备豁免,市场预审和De Novo途径批准的产品被归类为"高度创新".
- 510(k) 在2018-2022年间批准的产品被评估为儿科指示.
主要成果:
- 只有0.5%的510(k) 设备是专门用于儿科的;8.3%包括儿科指示.
- 在高度创新的设备中,只有2%是专为儿科的,2%包括儿科适用.
- 大型和中型公司比小型公司更有可能开发具有儿科指示的设备.
结论:
- 儿科骨科设备的创新远远落后于成人设备.
- 这些发现与修改成人植入物用于儿科的临床实践一致.
- 尽管有努力,儿童骨科器械创新的进展仍然有限.
相关概念视频
Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


